A double-blind, randomized-controlled trial using a low dose of ketamine vs. active placebo in treating severe depression and suicide.

A double-blind, randomized-controlled trial using a low dose of ketamine vs. active placebo in treating severe depression and suicide. - Efficacy of a low dose of ketamine infusion for the rapid anti-depression and anti-suicidal ideations.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000033916

Enrollment

Registered

2021-11-30

Start date

2018-08-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major depression including unipolar and bipolar depression

Interventions

0.5mg/kg Ketamine 0.045mg/kg Midazolam

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Major depression including unipolar and bipolar depression, according to DSM-IV criteria and MINI (MiniInternational Neuropsychiatric Interview;MINI) diagnostic interview. 2)voluntary patients with signed informed consent proved by institutional review board (IRB)

Exclusion criteria

Exclusion criteria: 1)Major medical conditions (e.g., head injury, epilepsy, severe renal diseases and cancer). 2)Other axis I psychiatric disorders such as schizophrenia, delusional disorder, organic brain syndrome, and dementia. 3)Pregnancy. 4)Substance abuse in previous 6 months. 5)Current use of NMDA receptor antagonist. 6)Attempt suicide in hospital.

Design outcomes

Primary

Measure	Time frame
Decreasing rate of suicide symptom postinfusion of ketamine	—

Countries

Asia(except Japan)

Contacts

Public ContactMu-Hong Chen

Taipei Veterans General Hospital, Taiwan Department of Psychiatry

kremer7119@gmail.com+886228712121

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026